> In biopharma specifically, one great bottleneck is clinical trials

It is a good news for having more intelligence. Phase 1 trial to acceptance rate is ~10%. If say in ideal world, intelligent AI could make it to 80% by rejecting drugs before Phase 1, cost of trial(which author claims is the bottleneck) would suddenly drop to 1/8th even if AI doesn't help at all in the trial.